Search Results - "Madden, Andrew J."

Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy by Chu, Kevin S, Schorzman, Allison N, Finniss, Mathew C, Bowerman, Charles J, Peng, Lei, Luft, James C, Madden, Andrew J, Wang, Andrew Z, Zamboni, William C, DeSimone, Joseph M

“…Abstract Nanoparticle (NP) drug loading is one of the key defining characteristics of an NP formulation. However, the effect of NP drug loading on therapeutic…”
Get full text

Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases by Song, Gina, Petschauer, Jennifer S, Madden, Andrew J, Zamboni, William C

“…Nanoparticles (NPs) provide several advantages over the small molecule drugs including prolonged circulation time and enhanced delivery to targeted sites. Once…”
Get more information

Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model by Price, Lauren S.L., Rivera, Judith N., Madden, Andrew J., Herity, Leah B., Piscitelli, Joseph A., Mageau, Savannah, Santos, Charlene M., Roques, Jose R., Midkiff, Bentley, Feinberg, Nana N., Darr, David, Chang, Sha X., Zamboni, William C.

“…Background: Minibeam radiation therapy is an experimental radiation therapy utilizing an array of parallel submillimeter planar X-ray beams. In preclinical…”
Get full text

The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents by Petschauer, Jennifer S, Madden, Andrew J, Kirschbrown, Whitney P, Song, Gina, Zamboni, William C

“…Major advances in carrier-mediated agents, which include nanoparticles, nanosomes and conjugates, have revolutionized drug delivery capabilities over the past…”
Get full text

Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer by Madden, Andrew J, Oberhardt, Bruce, Lockney, Dustin, Santos, Charlene, Vennam, Preethi, Arney, David, Franzen, Stefan, Lommel, Steven A, Miller, C Ryan, Gehrig, Paola, Zamboni, William C

“…To compare the pharmacokinetics and efficacy of doxorubicin containing plant virus nanoparticles (PVNs) with PEGylated liposomal doxorubicin (PLD) and small…”
Get full text

Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs by Lucas, Andrew T., Herity, Leah B., Kornblum, Zack A., Madden, Andrew J., Gabizon, Alberto, Kabanov, Alexander V., Ajamie, Rose T., Bender, David M., Kulanthaivel, Palaniappan, Sanchez-Felix, Manuel V., Havel, Henry A., Zamboni, William C.

“…[Display omitted] Studies have shown that nanoparticles (NPs) are cleared through the mononuclear phagocyte system (MPS). Pharmacokinetic studies of Doxil,…”
Get full text

Challenges in preclinical to clinical translation for anticancer carrier-mediated agents by Lucas, Andrew T., Madden, Andrew J., Zamboni, William C.

“…Major advances in carrier‐mediated agents (CMAs), which include nanoparticles and conjugates, have revolutionized drug delivery capabilities over the past…”
Get full text

Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents by Lucas, Andrew T, Madden, Andrew J, Zamboni, William C

“…Major advances in carrier-mediated agents (CMAs), which include nanoparticles and conjugates, have revolutionized drug delivery capabilities over the past…”
Get more information

Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT) by Madden, Andrew J., Rawal, Sumit, Sandison, Katie, Schell, Ryan, Schorzman, Allison, Deal, Allison, Feng, Lan, Ma, Ping, Mumper, Russell, DeSimone, Joseph, Zamboni, William C.

“…The pharmacokinetics (PK) of carrier-mediated agents (CMA) is dependent upon the carrier system. As a result, CMA PK differs greatly from the PK of small…”
Get full text

2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model by Peng, Lei, Schorzman, Allison N, Ma, Ping, Madden, Andrew J, Zamboni, William C, Benhabbour, Soumya Rahima, Mumper, Russell J

“…A nanoparticle (NP) formulation with 2'-(2-bromohexadecanoyl)-paclitaxel (Br-16-PX) conjugate was developed in these studies for the treatment of non-small…”
Get full text

Abstract 5051: Comparison of microbeam versus conventional broadbeam radiation therapy on tumor delivery enhancement of PEGylated liposomal doxorubicin in a triple negative breast cancer mouse model by Chang, Sha X., Rivera, Judith N., Herity, Leah B., Price, Lauren S., Madden, Andrew J., Roques, Jose R., Santos, Charlene, Darr, David, Zamboni, William C.

“…Background: Recent meta-analyses have reported that the tumor delivery of nanoparticles (NPs) is lower than expected and inefficient. Thus, there is a strong…”
Get full text

Abstract 3355: Evaluation of the efficiency of tumor and tissue delivery of carrier mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric relative distribution index over time (RDI-OT) by Madden, Andrew J., Rawal, Sumit, Chu, Kevin, Sandison, Katie, Schell, Ryan, Feng, Lan, Ma, Ping, Mumper, Russell, DeSimone, Joseph, Zamboni, William C.

“…Background: The PK of CMA are dependent upon the carrier system. As a result, CMA PK differ greatly from the PK of SM drugs. Advantages of CMA included…”
Get full text